CONCERTA/Methylphenidate — Sales to customers (Note 9)
Johnson & Johnson CONCERTA/Methylphenidate — Sales to customers (Note 9) increased by 3.0% to $136.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.1%, from $148.00M to $136.00M. Over 4 years (FY 2021 to FY 2025), CONCERTA/Methylphenidate — Sales to customers (Note 9) shows a downward trend with a -3.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market adoption or higher prescription volumes, while a decrease may signal increased generic competition or a shift in therapeutic treatment patterns.
Detailed definition
This metric represents the total net revenue generated from the sale of Concerta and related methylphenidate products to...
Peer comparison
Comparable to branded pharmaceutical product revenue lines reported by peers in the CNS or ADHD therapeutic categories.
jnj_segment_concerta_methylphenidate_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $161.00M | $157.00M | $178.00M | $157.00M | $161.00M | $158.00M | $168.00M | $206.00M | $208.00M | $189.00M | $180.00M | $177.00M | $163.00M | $142.00M | $159.00M | $148.00M | $164.00M | $140.00M | $132.00M | $136.00M |
| QoQ Change | — | -2.5% | +13.4% | -11.8% | +2.5% | -1.9% | +6.3% | +22.6% | +1.0% | -9.1% | -4.8% | -1.7% | -7.9% | -12.9% | +12.0% | -6.9% | +10.8% | -14.6% | -5.7% | +3.0% |
| YoY Change | — | — | — | — | +0.0% | +0.6% | -5.6% | +31.2% | +29.2% | +19.6% | +7.1% | -14.1% | -21.6% | -24.9% | -11.7% | -16.4% | +0.6% | -1.4% | -17.0% | -8.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's concerta/methylphenidate — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported concerta/methylphenidate — sales to customers (note 9) of $136.00M in Q1 2026.
- How has Johnson & Johnson's concerta/methylphenidate — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's concerta/methylphenidate — sales to customers (note 9) decreased by 8.1% year-over-year, from $148.00M to $136.00M.
- What is the long-term trend for Johnson & Johnson's concerta/methylphenidate — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's concerta/methylphenidate — sales to customers (note 9) has grown at a -3.3% compound annual growth rate (CAGR), from $667.00M to $584.00M.
- What does concerta/methylphenidate — sales to customers (note 9) mean?
- The total revenue earned from selling Concerta and methylphenidate products to customers.